Physician profile
Leander Cannick
NPI 1881705671
$3,207.06
in general payments reported to CMS, 2019-2025
54 companies · $535 in 2025
The $535 reported for 2025 was more than what 76% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $404 · 2020: $279 · 2021: $322 · 2022: $539 · 2023: $498 · 2024: $629 · 2025: $535.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,663.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $333.54 | 2019-2025 | |
| Eisai INC. | $245.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $181.43 | 2019-2025 | Calquence, Tagrisso |
| Seagen INC. | $162.27 | 2019-2023 | Padcev |
| Janssen Biotech, INC. | $138.91 | 2019-2025 | Erleada |
| Boston Scientific Corporation | $138.27 | 2019-2024 | Spaceoar Vue System - 10ml |
| Amgen INC. | $129.23 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $121.58 | 2021-2025 | |
| Incyte Corporation | $100.81 | 2019-2025 | Monjuvi, Zynyz |
| Galvanize Therapeutics, INC | $98.10 | 2025 | Aliya System |
| Merck Sharp & Dohme LLC | $88.66 | 2021-2025 | Keytruda |
| Progenics Pharmaceuticals, INC. | $85.70 | 2024 | |
| Sumitomo Pharma America, INC. | $75.77 | 2023 | Orgovyx |
| Celgene Corporation | $73.25 | 2021-2024 | Reblozyl, Opdualag |
| Jazz Pharmaceuticals INC. | $71.37 | 2021-2023 | Zepzelca |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leander Cannick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.